Imaging agent developer ImaginAb has inked a collaboration and commercialization agreement with Danish pharmaceutical firm H. Lundbeck.
Under the terms of the deal, the two companies will collaborate on imaging of the central nervous system to investigate the use of re-engineered antibodies for accelerating the transport of biologic agents across the blood-brain barrier (BBB). Lundbeck and ImaginAb will collaborate to concurrently develop biologics with improved BBB transport, as well as imaging agents that are capable of quantifying kinetics and targeting efficacy, according to the firms.
The agreement also includes an option for Lundbeck to commercialize the results of the collaboration for both diagnostic and therapeutic uses.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
